PRESS RELEASE published on 11/07/2025 at 14:00, 4 months 10 days ago Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Sanofi and Regeneron announce positive results from Dupixent pivotal study in allergic fungal rhinosinusitis, with sBLA accepted for FDA priority review FDA Sanofi Dupixent Regeneron AFRS
PRESS RELEASE published on 10/24/2025 at 07:30, 4 months 24 days ago Press release: Q3: continued sales and earnings progress
BRIEF published on 10/20/2025 at 13:35, 4 months 28 days ago Sanofi's Tzield: FDA Fast-Tracks Review for Type 1 Diabetes FDA Sanofi Type 1 Diabetes Expedited Review Tzield
PRESS RELEASE published on 10/20/2025 at 13:30, 4 months 28 days ago Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program Sanofi's Tzield accepted for expedited review by FDA under National Priority Voucher pilot program to delay progression of stage 3 type 1 diabetes. Breakthrough therapy with significant unmet medical need addressed FDA Sanofi Type 1 Diabetes Tzield National Priority Voucher
BRIEF published on 10/20/2025 at 08:35, 4 months 28 days ago Sanofi's AlphaMedix Shows Promise in Treating GEP-NETs Phase 2 Study Sanofi AlphaMedix GEP-NETs Targeted Alpha Therapy
PRESS RELEASE published on 10/20/2025 at 08:30, 4 months 28 days ago Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New phase 2 data presented at ESMO Congress highlight AlphaMedix as a promising targeted alpha therapy for GEP-NETs, showing high response rates and potential to address unmet medical needs ESMO Congress AlphaMedix Phase 2 Data GEP-NETs Targeted Alpha Therapy
BRIEF published on 10/20/2025 at 07:05, 4 months 28 days ago Sanofi's High-Dose Flu Vaccine Shows Enhanced Protection for Seniors Sanofi Flu Vaccine Senior Health Hospitalization Reduction FLUNITY-HD Study
PRESS RELEASE published on 10/20/2025 at 07:00, 4 months 28 days ago Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet Older Adults Sanofi Influenza Vaccine FLUNITY-HD Study Hospitalizations
BRIEF published on 10/17/2025 at 13:10, 5 months ago Sanofi's Wayrilz recommended by CHMP for IPT Sanofi CHMP BTK Inhibitor Wayrilz Immune Thrombocytopenia
BRIEF published on 10/17/2025 at 13:05, 5 months ago Sanofi faces negative EU opinion on Rezurock Europe Sanofi CHMP Rezurock CGVHD
Published on 03/18/2026 at 01:25, 1 hour 59 minutes ago Zeus North America Mining Corp. Announces Upsizing and Closing of Final Tranche of Private Placement
Published on 03/18/2026 at 00:30, 2 hours 54 minutes ago Panther Minerals Announces Appointment of Rick Mah as Chief Financial Officer
Published on 03/18/2026 at 00:30, 2 hours 54 minutes ago Core Critical Metals Corp. Announces Non-Brokered LIFE Offering and Concurrent Private Placement
Published on 03/17/2026 at 23:59, 3 hours 25 minutes ago Presentation to Swiss Mining Institute Conference
Published on 03/17/2026 at 23:10, 4 hours 14 minutes ago Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 23:43, 3 hours 41 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C - Daily buy back notice
Published on 03/17/2026 at 21:21, 6 hours 3 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 6 hours 28 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 9 hours 26 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 20 hours 24 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 9 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 9 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 9 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026